Phase IIb

Type: Keyphrase

Name: Phase IIb

First reported 1 hour ago - Updated 1 hour ago - 1 reports

Insiders at Lululemon and Restoration Hardware Sell Company Stock

Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside sales and purchases filed with the SEC on Wednesday, May 22, 2013.Purchases: The medical-centric investment firm bought 680,471 shares of biopharmaceutical ... [Published Yahoo! Finance - 1 hour ago]

Entities: Lululemon Athletica Inc, Restoration Hardware Inc, Stocks

First reported 1 hour ago - Updated 1 hour ago - 1 reports

Cash-strapped biotech fails PhIII test for pioneering Fragile X drug

Randall Carpenter, CEO of Seaside TherapeuticsSeaside Therapeutics has revealed its second failed study for its lead drug STX209 this month. In one of two Phase III studies for the compound for the genetic mental disorder Fragile X syndrome, STX209 treatment ... [Published FierceBiotech - 1 hour ago]

Entities: Drugs, Autism, Phase III

First reported 5 hours ago - Updated 5 hours ago - 1 reports

Creabilis announces encouraging results from Phase IIb psoriasis trial

Creabilis, a biotechnology company, has announced results from the company's Phase IIb trial with CT327, in psoriasis patients. CT327 is a novel, topical, TrkA kinase inhibitor developed using Creabilis' LSE (Low Systemic Exposure) technology that creates ... [Published Individual.com - 5 hours ago]

Entities: Psoriasis, Phase IIb, Patient

First reported 9 hours ago - Updated 9 hours ago - 1 reports

WHO Publishes Draft On Revised Process Validation Guideline: Validation Life-Cycle Required

The WHO has published a proposal for the revision of its supplementary guideline on GMP validation (Annex 7: non-sterile process validation). The document contains 11 pages divided in:Background and scopeGlossaryIntroductionPhase I. Process designPhase ... [Published Pharmaceutical Online - 9 hours ago]

Entities: Process Validation, Phase IIb, State of Control

First reported 14 hours ago - Updated 14 hours ago - 1 reports

Elcelyx Begins Patient Enrolment in Phase IIb Trial of Newmet for Type 2 Diabetes

Elcelyx has started enrolling patients in a dose-finding trial for Newmet, a generic version of the insulin resistance drug metformin. Pharmabiz.com Full Issue ... [Published FDA News - 14 hours ago]

Entities: Elcelyx Therapeutics Inc, Phase IIb, Diabetes Type II, Patient

First reported 17 hours ago - Updated 17 hours ago - 4 reports

FDA Recommends Running Phase 2b Trial of Repros' Proellex-V

Repros Therapeutics (NASDAQ: RPRX) today announced it has met with the FDA regarding the clinical development of Proellex-V, the vaginally administered product, in the treatment of uterine fibroids. The FDA recommended that a Phase 2b study should be ... [Published Benzinga.com - 17 hours ago]

Entities: Phase IIb, Phase III, Repros Therapeutics Inc

First reported May 21 2013 - Updated May 22 2013 - 2 reports

Transgene Announces Completion of Enrollment in TRAVERSE, a Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer

Regulatory NewsTransgene SA (Paris:TNG) (Euronext Paris: TNG), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, today announced completion of enrollment ... [Published FinanzNachrichten.de - May 21 2013]

Entities: Pexa-Vec, Transgene SA, Tumor, Clinical trials, Liver Cancer

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Jennerex completes enrollment in Phase 2b trial of liver cancer drug

Jennerex Biotherapeutics has completed enrolling 120 patients in Phase 2b trial of Pexa-Vec (JX-594, pexastimogene devacirepvec) for the treatment of liver cancer. ... [Published PBR - News - May 22 2013]

Entities: Jennerex Biotherapeutics Inc, Phase IIb, Liver Cancer, antineoplastic

First reported May 21 2013 - Updated May 22 2013 - 1 reports

Oxygen Biotherapeutics Names Col. Charles L. Pamplin III, M.D., Chief Medical Officer

- Expertise in the development of numerous commercialized drugs and his military background to support Company’s development path -MORRISVILLE, N.C.--(BUSINESS WIRE ?At this stage, the board felt it is was important to elevate the medical and product ... [Published EON - May 21 2013]

Entities: Oxygen Biotherapeutics Inc, King Pharmaceuticals Inc, Internal Medicine, Clinical Pharmacology

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study

SAN DIEGORaymond T. Bartus ... [Published Bio-Medicine - May 21 2013]

Entities: Ceregene Inc, Phase IIb, San Diego (California, United States)

First reported May 21 2013 - Updated May 21 2013 - 2 reports

Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study

PR NewswireSAN DIEGO, May 21, 2013SAN DIEGORaymond T. BartusThese and other efficacy and safety data related to the CERE-120 program were presented, by invitation, at a symposium at the American Society for Gene and Cell Therapy annual meeting in Salt ... [Published Digital Journal - May 21 2013]

Entities: Ceregene Inc, Parkinson's Disease, Neuron, Phase IIb

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Affordable homes scheme goes from strength to strength

In response to the demand for more from councils and developers, a further procurement round of a ground-breaking scheme – which is already delivering over 1000 new affordable homes across Scotland – has been launched.The National Housing Trust initiative ... [Published Scottish Executive - May 21 2013]

Entities: Edinburgh (United Kingdom), Phase IIb, Scottish Government, Initiative

Quotes

"My biggest disappointment is the lack of investment by others in this field and that we're out there by ourselves hacking our way through the jungle" Carpenter said in the May 1 interview

Cash-strapped biotech fails PhIII test for pioneering Fragile X drug [Published FierceBiotech - 1 hour ago]

David Roblin, CMO of Creabilis, said: "Pruritus is a debilitating yet under-recognised symptom in psoriasis and in other dermatological and systemic diseases. It has a significant impact on patients' quality of life and is currently poorly treated. There are no licensed products available, nor an established standard of care. There is a significant unmet need for a targeted treatment of chronic pruritus that combines efficacy with a good safety profile. In this study, up to 77% of CT327 treated patients had no or mild pruritus by the end of therapy. Combined with its outstanding safety profile, CT327 has the potential to provide a great benefit to patients."

Creabilis announces encouraging results from Phase IIb psoriasis trial [Published Individual.com - 5 hours ago]

...which represents the third most deadly cancer in the world," stated Laurent Fischer, M D , president and chief executive officer of Jennerex. "The strong participation in this financing by our existing investors provides important validation of Pexa-Vec's clinical potential and their belief in our targeted oncolytic immunotherapy platform. We look forward to sharing data from the TRAVERSE PhasePhase 2b study that completed enrollment earlier this week."

Jennerex Completes $21.6 Million Private Placement [Published Zecco - 6 hours ago]

Aradigm president and CEO Igor Gonda said, "Grifols is a great fit for us with their global reach of respiratory physicians treating a number of conditions that could benefit from Pulmaquin." Latest News

Grifols, Aradigm sign licensing deal for inhaled ciprofloxacin formulations [Published Pharmaceutical Business Review - 10 hours ago]

More Content

sort by: Date \| Relevance
Insiders at Lululemon and Restoration Hardware ... [Published Minyanville - 1 hour ago]
Insiders at Lululemon and Restoration Hardware ... [Published Yahoo! Finance - 1 hour ago]
Cash-strapped biotech fails PhIII test for pion... [Published FierceBiotech - 1 hour ago]
CytRx to Present at the Marcum MicroCap Conference [Published EON: Enhanced Online News - 4 hours ago]
CytRx to Present at the Marcum MicroCap Confere... [Published Yahoo! Finance - 4 hours ago]
CYTRX CORPORATION: CytRx to Present at the Marc... [Published 4 Traders - 5 hours ago]
Creabilis announces encouraging results from Ph... [Published Individual.com - 5 hours ago]
Jennerex Completes $21.6 Million Private Placement [Published Zecco - 6 hours ago]
WHO Publishes Draft On Revised Process Validati... [Published Pharmaceutical Online - 9 hours ago]
Grifols, Aradigm sign licensing deal for inhale... [Published Pharmaceutical Business Review - 10 hours ago]
Grifols, S.A. Inks Licensing Pact with Aradigm ... [Published Individual.com - 12 hours ago]
Cytokinetics' CEO Hosts the Annual Meeting of S... [Published Seeking Alpha - 12 hours ago]
Elcelyx Begins Patient Enrolment in Phase IIb ... [Published FDA News - 14 hours ago]
FDA Recommends Running Phase 2b Trial of Repros... [Published Benzinga.com - 17 hours ago]
FDA Recommends Running Phase 2b Trial of Proell... [Published GlobeNewswire: Acquisitions News - 17 hours ago]
FDA Recommends Running Phase 2b Trial of Proell... [Published Reuters - 17 hours ago]
FDA Recommends Running Phase 2b Trial of Proell... [Published OSIX News - 17 hours ago]
FDA Recommends Running Phase 2b Trial of Proell... [Published Stockwatch - 17 hours ago]
Scott+Scott, Attorneys at Law, LLP Reminds Vent... [Published Zecco - 19 hours ago]
Regeneron Shareholders Watching Optina Trial Cl... [Published Seeking Alpha - 21 hours ago]
Rib-X Pharmaceuticals Appoints John E. Sununu t... [Published Equities.com - 22 hours ago]
GENFIT ANNOUNCES ITS ANNUAL GENERAL SHAREHOLDER... [Published Reuters - May 22 2013]
Acucela and Otsuka announce encouraging results... [Published Individual.com - May 22 2013]
Jennerex receives orphan drug designation from ... [Published Zecco - May 22 2013]
Stocks to Watch (UniPixel Inc, Real Goods Solar... [Published SBWire - May 22 2013]
Jennerex completes enrollment in Phase 2b trial... [Published PBR - News - May 22 2013]
AbbVie Initiates Phase 3 Study of Its Investiga... [Published MyNewsDesk - May 22 2013]
Amicus Therapeutics' CEO Presents at 2013 UBS G... [Published Seeking Alpha - May 22 2013]
SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed... [Published Scottrade - May 21 2013]
Grifols Signs Deal to License Aradigm Corporati... [Published BioSpace - May 21 2013]

sort by: Date \| Relevance
Jennerex completes enrollment in Phase 2b trial... [Published PBR - News - May 22 2013] Jennerex Biotherapeutics has completed enrolling 120 patients in Phase 2b trial of Pexa-Vec (JX-594, pexastimogene devacirepvec) for the treatment of liver cancer. ...
Apple Explores OLED For Its Smartwatch and 2 Ot... [Published Wall St. Cheat Sheet - May 20 2013] Apple ( NASDAQ:AAPL ): Current price $442.52Apple is said to be testing 1.5-inch OLED displays for its smartwatch, according to Dylan Love at Business Insider, from MacRumors. OLED constitutes the same display tech that is employed in higher-end televisions ...
Apple Explores OLED For Its Smartwatch and 2 Ot... [Published Wall St. Cheat Sheet - May 20 2013] Apple ( NASDAQ:AAPL ): Current price $442.52 Apple is said to be testing 1.5-inch OLED displays for its smartwatch, according to Dylan Love at Business Insider, from MacRumors. OLED constitutes the same display tech that is employed in higher-end ...
Deals Of The Week Is Keeping Score – Valeant Wa... [Published The IN VIVO Blog - May 17 2013] Whether the pastime is baseball, Broadway or the daytime soaps, the old adage is that you can’t keep track of the players without a scorecard. The M&A front involving specialty pharma and generic drug makers has become similarly frenzied, as Canada’s ...
Trevena, Inc. and Forest Laboratories Announce ... [Published Pharma-Mag - May 15 2013] Forest Laboratories Leads Trevena’s $60m Series C Funding Round; All Existing Investors to Also Participate Trevena, Inc., a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ...